First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)
This grant funds first-in-human and early-stage clinical trials for novel investigational drugs or neuromodulatory devices aimed at treating psychiatric disorders.
About this program
The grant supports clinical trials that are focused on innovative treatments for psychiatric disorders, specifically those that involve novel investigational drugs or neuromodulatory devices. It is designed for researchers and institutions that are conducting early-stage clinical trials to evaluate the safety and efficacy of these new interventions. The goal is to advance the understanding and treatment of psychiatric conditions through rigorous scientific investigation. Eligible applicants include academic institutions, research organizations, and other entities involved in clinical research. The funding will facilitate the necessary trials to gather data on the effectiveness of these novel approaches, ultimately contributing to improved therapeutic options for patients suffering from psychiatric disorders. This grant is critical for fostering innovation in mental health treatment and ensuring that promising new therapies can be tested in human subjects.
Eligibility
Academic institutions, research organizations, and other entities involved in clinical research.